Acute Respiratory Distress Syndrome Pipeline: Emerging Therapies and Key Pharmaceutical Players Involved by DelveInsight | Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel and others

0

“Acute Respiratory Distress Syndrome Pipeline”

Acute Respiratory Distress Syndrome (ARDS) Pipeline Preview, 2022“DelveInsight’s report provides comprehensive information on the current clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome (ARDS) market. A detailed picture of the Acute Respiratory Distress Syndrome (ARDS) the pipeline landscape is provided, which includes the disease overview and Acute Respiratory Distress Syndrome (ARDS) treatment guidelines.

The evaluation part of the report includes Acute Respiratory Distress Syndrome (ARDS) commercial evaluation and clinical evaluation of the Acute Respiratory Distress Syndrome (ARDS) pipeline of products from the preclinical development phase to the commercialization phase. In the report, a detailed description of the drug is offered, including the mechanism of action of the drug, clinical studies, NDA approvals (if any) and product development activities including technology, Acute Respiratory Distress Syndrome (ARDS) collaborations, licenses, mergers and acquisitions, financing, designations and other product-related details.

Leading players in the Acute Respiratory Distress Syndrome market are:

  • Faron Pharmaceuticals
  • BioMarck Pharmaceuticals
  • Techpool Bio-Pharma
  • Athersys
  • APEPTICO Forschung und Entwicklung GmbH
  • Apeiron Biologics/GlaxoSmithKline
  • GlaxoSmithKline
  • Implicit Bioscience
  • United Therapeutics

Sample page request: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-pipeline-insight

Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication of ARDS is fluid leaking into the lungs, which makes breathing difficult or impossible.

The causes of ARDS are divided into two categories: direct or indirect lung damage. Some of the direct lung injuries include pneumonia, aspiration, trauma and others. While indirect lung damage includes inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and drug reactions.

The few symptoms of ARDS are shortness of breath, cough, and fever. In some cases, people with ARDS also have rapid heart rate and breathing. Sometimes patients with ARDS experience chest pain, especially when inhaling. Some patients also experience bluish discoloration of the fingernails and lips due to the sharp decrease in blood oxygen levels. Several risk factors can increase the risk of ARDS. It involves obesity, alcohol abuse, chemotherapy, low protein in the blood.

Sample page request: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight

The launch of Emerging Therapies is expected to have a significant impact on the Acute Respiratory Distress Syndrome treatment scenario in the coming years:-

Drugs for acute respiratory distress syndrome covered:

  • Traumakin
  • Bio-11006
  • Ulinastatin
  • Multirod
  • Solnatide (AP301)
  • APN01 (GSK2586881)
  • GSK2862277
  • IC14
  • Remodulin (treprostinil inhalation solution)

Sample page request: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight

Analytical Perspective of Acute Respiratory Distress Syndrome (ARDS) by DelveInsight

  • Acute Respiratory Distress Syndrome (ARDS) In-Depth Commercial Evaluation of Products

This report provides a comprehensive business assessment of the therapeutic drugs that have been included, which includes collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (license/partnership), company-university collaborations and acquisition analysis in graphical and tabulated form in detail.

  • Acute Respiratory Distress Syndrome (ARDS) Clinical Evaluation of Products

The report includes a comparative clinical evaluation of the products by stage of development, product type, route of administration, molecule type and type of mode of action for this indication.

Scope of Acute Respiratory Distress Syndrome Report

  • The Acute Respiratory Distress Syndrome (ARDS) report provides an overview of therapeutic pipeline activity and therapeutic evaluation of products by stage of development, type of product, route of administration, type of molecule and type of MOA for Acute Respiratory Distress Syndrome (ARDS) throughout the product development cycle, including all clinical and non-clinical stages.
  • It includes of detailed profiles of Acute Respiratory Distress Syndrome (ARDS) therapeutic products with key coverage of development activities, including technology, collaborations, licensing, mergers and acquisitions, funding, designations and other product-related details
  • Detailed acute respiratory distress syndrome (ARDS) research and development progress and trial detailsthe results, when available, are also included in the pipeline study.
  • Inactive and Abandoned Pipeline Project Coverages along with the reasons if available in Acute Respiratory Distress Syndrome (ARDS).

Key Questions About Acute Respiratory Distress Syndrome

  • What are the current treatment options for acute respiratory distress syndrome (ARDS)?
  • How many companies are developing therapies for the treatment of acute respiratory distress syndrome (ARDS)?
  • What are the main therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
  • How many emerging therapies for acute respiratory distress syndrome (ARDS) are in early, middle and late stage development for the treatment of acute respiratory distress syndrome (ARDS)?
  • Of all the products in the pipeline, how many therapies are given as monotherapy and in combination with other therapies?
  • What are the major collaborations (industry-industry, industry-academia), mergers and acquisitions, and major licensing activities that will impact the Acute Respiratory Distress Syndrome (ARDS) market?
  • What are dormant and discontinued products and why?
  • What is the unmet need for current therapies for the treatment of acute respiratory distress syndrome (ARDS)?
  • What are the recent new treatments, targets, mechanisms of action and technologies developed to overcome the limitations of existing therapies for acute respiratory distress syndrome (ARDS)?
  • What are the ongoing clinical studies for Acute Respiratory Distress Syndrome (ARDS) and their status?
  • What are the results of clinical studies, their safety and effectiveness?
  • What are the key designations that have been given to emerging therapies for acute respiratory distress syndrome (ARDS)?
  • How many patents are granted and pending for emerging therapies for the treatment of acute respiratory distress syndrome (ARDS)?

Sample page request: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight

Contents:

1. Presentation of the report

2. Acute Respiratory Distress Syndrome (ARDS)

3. Current treatment regimens for acute respiratory distress syndrome (ARDS)

4. Acute Respiratory Distress Syndrome (ARDS) – Analytical Perspective from DelveInsight

5. Therapeutic assessment

6. Advanced Acute Respiratory Distress Syndrome (ARDS) Products (Phase III)

7. Mid-stage Acute Respiratory Distress Syndrome (ARDS) Products (Phase II)

8. Early Stage Products (Phase I)

9. Preclinical products and products in the discovery phase

10. Inactive Products

11. Dormant products

12. Discontinued Products for Acute Respiratory Distress Syndrome (ARDS)

13. Acute Respiratory Distress Syndrome (ARDS) Product Profiles

14. Key Acute Respiratory Distress Syndrome (ARDS) Societies

15. Key Acute Respiratory Distress Syndrome (ARDS) Products

16. Dormant and Discontinued Products

17. Unmet Needs of Acute Respiratory Distress Syndrome (ARDS)

18. Future Prospects of Acute Respiratory Distress Syndrome (ARDS)

19. Review by an analyst for acute respiratory distress syndrome (ARDS)

20. Appendix

21. Report Methodology

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing complete end-to-end solutions to improve their performance. Get hassle-free access to all healthcare and pharmaceutical industry market research reports through our subscription-based PharmDelve platform.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Ankit Nigam
E-mail: Send an email
Call: +19193216187
Address:304 S. Jones Boulevard #2432
Town: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-pipeline-insight

Share.

Comments are closed.